{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/trigeminal-neuralgia/","result":{"data":{"firstChapter":{"id":"5a46b0ae-84bb-5e91-9f06-d82e7de90660","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 695afd51-9aea-4904-8ef8-f5c7c07013ae --><h1>Trigeminal neuralgia: Summary</h1><!-- end field 695afd51-9aea-4904-8ef8-f5c7c07013ae -->","htmlStringContent":"<!-- begin item db520430-a268-48bc-8ce5-931c0c91a7ee --><!-- begin field 323ebb6e-25e7-47fe-a8cd-914811d4dc28 --><ul><li>Trigeminal neuralgia occurs in the distribution of one or more branches of the fifth (trigeminal) cranial nerve.</li><li>Pain may occur infrequently (e.g. periods of remission may last years) or with a frequency of up to hundreds of times a day.</li><li>In over 90% of cases, trigeminal neuralgia is thought to be caused by vascular compression of the trigeminal nerve.</li><li>Trigeminal neuralgia is more common in women than in men. The incidence increases with age and is rare in people younger than 40 years of age.</li><li>Complications include depression, and inability to eat causing weight loss.</li><li>Features of trigeminal neuralgia include paroxysmal attacks of pain which may be precipitated by trigger factors such as light touch to the face.</li><li>'Atypical' or 'mixed' trigeminal neuralgia occurs when there is a persistent discomfort between paroxysms.</li><li>The drug of choice for the treatment of trigeminal neuralgia is carbamazepine:<ul><li>Dose should be titrated until pain is relieved. In the majority of people, a dose of 200 mg three or four times a day is sufficient to prevent paroxysms of pain (maximum dosage 1,600 mg daily).</li><li>If carbamazepine is contraindicated, ineffective, or not tolerated, specialist advice should be sought, or referral made to a neurologist or a specialist in pain management. A daily pain diary may be useful to help people learn to manage their pain.</li><li>When the pain is in remission, the dose of carbamazepine should be reduced, and gradually withdrawn.</li></ul></li><li>Referral to a neurologist or a specialist in pain management should be considered if the person has severe pain that limits their daily acitivities.</li><li>Specialist referral, with the urgency determine by clinical judgment, is advised if there are atypical clinical features, or features suggestive of a serious underlying cause (e.g. sensory changes, deafness or other ear problems, history of skin or oral lesions that could spread perineurally, pain only in the ophthalmic division of the trigeminal nerve, or bilaterally, age of onset before 40 years, optic neuralgia, or a family history of multiple sclerosis).</li></ul><!-- end field 323ebb6e-25e7-47fe-a8cd-914811d4dc28 --><!-- end item db520430-a268-48bc-8ce5-931c0c91a7ee -->","topic":{"id":"b411a210-e8ef-56d4-8840-714bb3ca8b7d","topicId":"dd0f36c2-b31b-42ca-bc80-17ddb7e243ec","topicName":"Trigeminal neuralgia","slug":"trigeminal-neuralgia","aliases":[],"chapters":[{"id":"5a46b0ae-84bb-5e91-9f06-d82e7de90660","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"6ebb1131-0f9c-5613-9b6d-c44044dc3d59","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"04895c32-0679-538d-bd7f-566f3b1aca33","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"064b944d-9f86-5ad2-bdde-418e427a69cf","slug":"changes","fullItemName":"Changes"},{"id":"215b2ed2-a6ff-5053-b74a-72ca907fbb6f","slug":"update","fullItemName":"Update"}]},{"id":"0d57219c-f171-59f5-b932-8cabc9dd5049","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d78c8e6b-affd-55c5-8e55-1db5bbe57261","slug":"goals","fullItemName":"Goals"},{"id":"135b5ce1-adf5-5fa9-8d6a-a90e64183628","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2dd53a4e-0dcf-5797-90d1-ac0ae3a56a93","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8fd6b61-b1c3-538d-b032-872f1d3427c2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d867bfa-0e88-5dbe-85c4-50f28d24c9c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"38f48973-5497-53e5-a936-4b59cbd4b662","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff1b2d66-75ed-51c6-bfa9-fcc0ad6d6bac","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2e9fdd75-4a7e-56ad-8c9d-02ac90da26bd","slug":"definition","fullItemName":"Definition"},{"id":"4dc2aba7-3510-51d4-9aab-2596d348bd1a","slug":"causes","fullItemName":"Causes"},{"id":"6e2bbd60-dabb-5cdb-86d0-29bd0a23615b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7c45985c-eb6e-5f96-9d9b-44cc50b51476","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16848fcb-77c6-5043-9c84-eadffb6ff3aa","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7f1ea99-b3b5-5e53-952d-515327e12d83","slug":"complications","fullItemName":"Complications"}]},{"id":"5c22d7af-254a-51f1-a8b9-07efa299f48b","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"bbf28df3-9b64-5c32-85b5-26dc3c2cc0af","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"feea47e1-4766-5814-8cd9-3adf7df4600f","slug":"management","fullItemName":"Management","subChapters":[{"id":"5008bdc5-02f7-558d-9c72-fa0bd4f2c01a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ff7b11db-4087-5134-804a-f231a32cf2ce","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"74b691ce-0764-54e6-a932-11f0755c3089","slug":"carbamazepine","fullItemName":"Carbamazepine"}]},{"id":"ae57d488-a470-558c-b5d7-81fb47f8fbad","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"90e907d0-34e8-53cc-a9f6-53b0de5c633c","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c39bcb69-119d-5f65-927c-00c82813d6f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"614a98b5-320e-5735-b0f4-c72808b83068","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4c55bb70-6e39-5673-898f-4244d6e219e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8a3490-a3c6-565b-9f06-fc347a6c2eb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12e3df2a-fa39-57fa-b4ef-e222cd41fa5b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d1abb506-cecf-562c-84a9-1e2167e7129f","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"b411a210-e8ef-56d4-8840-714bb3ca8b7d","topicId":"dd0f36c2-b31b-42ca-bc80-17ddb7e243ec","topicName":"Trigeminal neuralgia","slug":"trigeminal-neuralgia","aliases":[],"topicSummary":"Trigeminal neuralgia occurs in the distribution of one or more branches of the fifth (trigeminal) cranial nerve.","lastRevised":"Last revised in January 2018","nextPlannedReviewBy":"2022-03-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2022-03","nextPlannedReviewByDisplay":"March 2022","specialities":[{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"}],"chapters":[{"id":"5a46b0ae-84bb-5e91-9f06-d82e7de90660","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"6ebb1131-0f9c-5613-9b6d-c44044dc3d59","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"04895c32-0679-538d-bd7f-566f3b1aca33","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"064b944d-9f86-5ad2-bdde-418e427a69cf","slug":"changes","fullItemName":"Changes"},{"id":"215b2ed2-a6ff-5053-b74a-72ca907fbb6f","slug":"update","fullItemName":"Update"}]},{"id":"0d57219c-f171-59f5-b932-8cabc9dd5049","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d78c8e6b-affd-55c5-8e55-1db5bbe57261","slug":"goals","fullItemName":"Goals"},{"id":"135b5ce1-adf5-5fa9-8d6a-a90e64183628","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2dd53a4e-0dcf-5797-90d1-ac0ae3a56a93","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8fd6b61-b1c3-538d-b032-872f1d3427c2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d867bfa-0e88-5dbe-85c4-50f28d24c9c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"38f48973-5497-53e5-a936-4b59cbd4b662","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff1b2d66-75ed-51c6-bfa9-fcc0ad6d6bac","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2e9fdd75-4a7e-56ad-8c9d-02ac90da26bd","slug":"definition","fullItemName":"Definition"},{"id":"4dc2aba7-3510-51d4-9aab-2596d348bd1a","slug":"causes","fullItemName":"Causes"},{"id":"6e2bbd60-dabb-5cdb-86d0-29bd0a23615b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"7c45985c-eb6e-5f96-9d9b-44cc50b51476","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16848fcb-77c6-5043-9c84-eadffb6ff3aa","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a7f1ea99-b3b5-5e53-952d-515327e12d83","slug":"complications","fullItemName":"Complications"}]},{"id":"5c22d7af-254a-51f1-a8b9-07efa299f48b","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"bbf28df3-9b64-5c32-85b5-26dc3c2cc0af","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"feea47e1-4766-5814-8cd9-3adf7df4600f","slug":"management","fullItemName":"Management","subChapters":[{"id":"5008bdc5-02f7-558d-9c72-fa0bd4f2c01a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ff7b11db-4087-5134-804a-f231a32cf2ce","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"74b691ce-0764-54e6-a932-11f0755c3089","slug":"carbamazepine","fullItemName":"Carbamazepine"}]},{"id":"ae57d488-a470-558c-b5d7-81fb47f8fbad","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"90e907d0-34e8-53cc-a9f6-53b0de5c633c","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c39bcb69-119d-5f65-927c-00c82813d6f3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"614a98b5-320e-5735-b0f4-c72808b83068","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4c55bb70-6e39-5673-898f-4244d6e219e7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8a3490-a3c6-565b-9f06-fc347a6c2eb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"12e3df2a-fa39-57fa-b4ef-e222cd41fa5b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d1abb506-cecf-562c-84a9-1e2167e7129f","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"b411a210-e8ef-56d4-8840-714bb3ca8b7d"}},"staticQueryHashes":["3666801979"]}